Ameresco Awarded 2023 North American Energy Services Company of the Year by Frost & Sullivan

Ameresco Awarded 2023 North American Energy Services Company of the Year by Frost & Sullivan

Leading cleantech integrator receives recognition for best practices in customer impact, visionary innovation and performance

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Ameresco, Inc., (NYSE: AMRC), a leading cleantech integrator specializing in energy efficiency and renewable energy, today announced that it has been awarded the 2023 North American Energy Services Company of the Year by Frost & Sullivan, a market research firm that recognizes organizations that exemplify market-leading performance and exemplary innovation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005599/en/

Ameresco was selected due to its demonstrated excellence in the energy services space, particularly as it relates to customer impact and visionary transformation and performance. As a long-term trusted energy partner for organizations across North America, Ameresco has leveraged its two decades of experience to deliver over $13 billion in projects for governmental, utility, institutional, commercial, and industrial customers. Ameresco’s strong financial performance, coupled with its customer-centric approach and significant growth potential, led to its selection for this recognition.

“At Ameresco, our vision is to energize a sustainable world by helping our clients achieve their energy efficiency and sustainability goals. We are honored and humbled to be recognized by Frost & Sullivan with the Best Practices Award for our commitment to this vision through innovation and excellence in the energy industry,” said George Sakellaris, President and CEO of Ameresco. “This recognition is a testament to the hard work and dedication of our team, and we are grateful to have such a talented group of professionals driving our mission forward. Thank you to Frost & Sullivan for this recognition, and we look forward to continuing to push the boundaries of what’s possible in clean energy.”

Frost & Sullivan utilizes a rigorous analytical process to judge nominees across award categories to determine the final award recipient. Recipients are selected based on demonstration of best practices across criteria, such as addressing unmet customer needs, making sure to focus on leadership, and working to upgrade their financial performance.

“This year’s recipient of the North American Energy Services Company of the Year Award has shown to be a role model and leading cleantech provider within the industry,” said Maria Benintende, Industry Director, Energy & Environment Frost & Sullivan. “We are thrilled to honor Ameresco with this award for the company’s commitment to developing and implementing comprehensive solution sets that enable a more sustainable future.”

The Frost & Sullivan 2023 North American Energy Services Company of the Year Award was awarded to Ameresco in April 2023.

To learn more about Frost & Sullivan’s selection of Ameresco and read the full award writeup, visit https://info.ameresco.com/frost-and-sullivan-award-23.

About Ameresco, Inc.

Founded in 2000, Ameresco, Inc. (NYSE:AMRC) is a leading cleantech integrator and renewable energy asset developer, owner and operator. Our comprehensive portfolio includes energy efficiency, infrastructure upgrades, asset sustainability and renewable energy solutions delivered to clients throughout North America and Europe. Ameresco’s sustainability services in support of clients’ pursuit of Net Zero include upgrades to a facility’s energy infrastructure and the development, construction, and operation of distributed energy resources. Ameresco has successfully completed energy saving, environmentally responsible projects with Federal, state and local governments, healthcare and educational institutions, housing authorities, and commercial and industrial customers. With its corporate headquarters in Framingham, MA, Ameresco has more than 1,000 employees providing local expertise in the United States, Canada, and Europe. For more information, visit www.ameresco.com.

About Frost & Sullivan

Frost & Sullivan is the Growth Pipeline CompanyTM. We power our clients to a future shaped by growth. Our Growth Pipeline as a ServiceTM provides the CEO and the CEO’s growth team with a continuous and rigorous platform of growth opportunities, ensuring long-term success. To achieve positive outcomes, our team leverages over 60 years of experience, coaching organizations of all types and sizes across 6 continents with our proven best practices. To power your Growth Pipeline future, visit Frost & Sullivan at http://www.frost.com.

Ameresco: Leila Dillon, 508-661-2264, [email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Other Energy Architecture Other Construction & Property Alternative Energy Energy Construction & Property

MEDIA:

Logo
Logo
Logo
Logo

Datasea Strengthens Sales Growth and Expands Business with Top-Tier 5G Messaging Recharge Payment Platform

BEIJING, April 18, 2023 (GLOBE NEWSWIRE) — Datasea Inc., (NASDAQ: DTSS) (“Datasea” or the “Company”), incorporated in Nevada in September 2014, is a digital technology corporation engaged in three converging and innovative business segments: 5G messaging, acoustic intelligence, and smart city technology in China. Today, the Company announced that on February 16, 2023, Hangzhou Shuhai Zhangxun Technology Co., Ltd. (“Shuhai Zhangxun”), a subsidiary of the Chinese operating company contractually controlled by the Company, has entered into a cooperation agreement with Hangzhou Chongda Technology Co., Ltd. (“Chongda”) to enhance 5G messaging recharge services in the Chinese market.

Under the agreement, Chongda can purchase up to 1.1 million virtual recharge cards of various denominations for 5G messaging within 12 months commencing from February 16, 2023, with a maximum total value of approximately USD 29.81 million (RMB 205 million). Since the date of the agreement until the date of this announcement, Shuhai Zhangxun has provided end-users with 5G messaging recharge services worth approximately USD 0.85 million (RMB 5,821,427), demonstrating the Company’s unwavering commitment to the 5G messaging market in China.

Chongda, a leading provider of marketing services, offers high-quality mobile phone plans, prepaid oil recharge plans, and prepaid electricity recharge plans to tens of thousands of domestic companies, e-commerce platforms, and individuals. The collaboration agreement between Shuhai Zhangxun and Chongda exemplifies that Shuhai Zhangxun is actively providing and shall continue providing 5G messaging recharge plans, data interfaces, and a 5G messaging recharge payment platform for recharge services and related management.

The demand for 5G messaging services in China is high, and Datasea has proven its ability to provide top-tier services to its customers, providing 5G messaging-related recharge services worth approximately USD 0.85 million to end-users. This achievement underscores Datasea’s unwavering dedication to delivering efficient and customized recharge services to individual and enterprise users.

Datasea’s CEO, Zhixin Liu, expressed her satisfaction with the collaboration’s progress, emphasizing the importance of identifying potential customers that need their 5G messaging delivery services, and providing efficient and stable 5G messaging services to customers quickly. By doing so, Ms. Zhixin Liu believes that Datasea can capitalize on more opportunities for revenue growth and is in line with its mission to become a leading provider of digital technology solutions in China.

The Company believes that the cooperation agreement between Shuhai Zhangxun and Chongda reinforces Datasea’s position as a leading provider of 5G messaging services in China. Datasea’s ability to provide top-tier services to businesses at scale is a testament to its commitment to delivering efficient and customized recharge services to its customers.

About Datasea Inc.

Datasea Inc., through its variable interest entity, Shuhai Information Technology Co., Ltd., a digital technology company in China, engages in three converging and innovative industries: smart city, acoustic intelligence and 5G messaging. Datasea leverages facial recognition technology and other visual intelligence algorithms, combined with cutting-edge acoustic and non-visual intelligence algorithms, to provide smart city solutions that meet the security needs of residential communities, schools and commercial enterprises. Most recently, in response to the growing utilization of 5G technologies and the overall initiative to utilize Datasea’s technology capabilities to expand business coverage and revenue resources, Datasea has also strategically expanded business coverage to 5G messaging and smart payment solutions. Datasea has been certified as one of the High-Tech Enterprises (jointly issued by the Beijing Science and Technology Commission, Beijing Finance Bureau, Beijing State Taxation Bureau and Beijing Local Taxation Bureau) and one of the Zhongguancun High Tech Enterprises (issued by the Zhongguancun Science Park Administrative Committee) in recognition of the Company’s achievement in high technology products. For additional information, please visit: www.dataseainc.com. Datasea routinely posts important information on its website.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook,” “objective” and similar terms. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond Datasea’s control, which may cause Datasea’s actual results, performance or achievements  (including the RMB/USD value of its anticipated benefit to Datasea as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Datasea’s filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Datasea does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Investor and Media Contact: 

International Elite Capital Inc. 
Annabelle Zhang
Telephone: +1(646) 866-7989 
Email: [email protected]



Global Water Resources Sets First Quarter 2023 Conference Call for Wednesday, May 3, 2023 at 1:00 p.m. ET

PHOENIX, April 18, 2023 (GLOBE NEWSWIRE) — Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, will hold a conference call on Wednesday, May 3, 2023 at 1:00 p.m. Eastern time to discuss results for the first quarter ended March 31, 2023. The financial results will be issued in a press release prior to the call.

Global Water Resources management will host the presentation, followed by a question-and-answer period.

Date: Wednesday, May 3, 2023
Time: 1:00 p.m. Eastern time (10:00 a.m. Pacific time)
Toll-free dial-in number: 1-844-825-9789
International dial-in number: 1-412-317-5180
Conference ID: 10178129
Webcast (live and replay): here

The conference call webcast is also available via a link in the Investors section of the company’s website at www.gwresources.com.

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.

A replay of the call will be available after 4:00 p.m. Eastern time on the same day through May 17, 2023.

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 10178129

About Global Water Resources
Global Water Resources, Inc. is a leading water resource management company that owns and operates 29 systems which provide water, wastewater, and recycled water services. The company’s service areas are located primarily in growth corridors around metropolitan Phoenix. Global Water recycles over 1 billion gallons of water annually.

The company has been recognized for its highly effective implementation of Total Water Management (TWM). TWM is an integrated approach to managing the entire water cycle that involves owning and operating water, wastewater, and recycled water utilities within the same geographic area in order to maximize the beneficial use of recycled water. It enables smart water management programs such as remote metering infrastructure and other advanced technologies, rate designs, and incentives that result in real conservation. TWM helps protect water supplies in water-scarce areas experiencing population growth.

Global Water has received numerous industry awards, including national recognition as a ‘Utility of the Future Today’ for its superior water reuse practices by a national consortium of water and conservation organizations led by the Water Environment Federation (WEF). The company also received Cityworks’ 2022 Excellence in Departmental Practice Award for demonstrating leadership and creativity in applying public asset management strategies to daily operations and long-term planning.

To learn more, visit www.gwresources.com.

Company Contact:

Michael Liebman
CFO and SVP
Tel (480) 999-5104
[email protected]

Investor Relations Contact:

Ron Both or Grant Stude
CMA
Tel (949) 432-7566
Email contact

Media & ESG Contact:

Tim Randall
CMA
Tel (949) 432-7572
Email Contact



International Money Express to Release First Quarter 2023 Earnings

MIAMI, April 18, 2023 (GLOBE NEWSWIRE) — International Money Express, Inc. (NASDAQ: IMXI) (the “Company” or “Intermex”), will release its First Quarter 2023 earnings before the start of trading on Thursday, May 4, 2023. Management will host a conference call on May 4, 2023, at 9:00 am ET to discuss the Company’s financial and operating results. The conference call can be accessed as follows:

An audio replay of the conference call will be available from approximately 12:00 pm ET on May 4, 2023, until 11:59 pm ET on May 18, 2023, and can be accessed by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international), and providing the passcode 15183700 or by accessing Intermex’s website at https://investors.intermexonline.com/.

About International Money Express, Inc.

Founded in 1994, Intermex applies proprietary technology enabling consumers to send money from the United States, Canada, and Europe to more than 60 countries. The Company provides the digital movement of money through a network of agent retailers in the United States, Canada, and Europe; Company-operated stores; mobile app; and via the Company’s website. Transactions are fulfilled and paid through thousands of retail and bank locations worldwide. Intermex is headquartered in Miami, Florida, with international offices in Puebla, Mexico, Guatemala City, Guatemala, and Madrid, Spain. For more information about Intermex, please visit www.intermexonline.com.

Investor Relations:

Mike Gallentine
Vice President of Investor Relations
tel: 305-671-8005
[email protected]



CVR Energy to Release First Quarter 2023 Earnings Results

SUGAR LAND, Texas, April 18, 2023 (GLOBE NEWSWIRE) — CVR Energy, Inc. (NYSE: CVI) plans to release its first quarter 2023 earnings results on Monday, May 1, after the close of trading on the New York Stock Exchange. The Company also will host a teleconference call on Tuesday, May 2, at 1 p.m. Eastern to discuss these results.

This call, which will contain forward-looking information, will be webcast live and can be accessed on the Investor Relations section of CVR Energy’s website at www.CVREnergy.com. For investors or analysts who want to participate during the call, the dial-in number is (877) 407-8291. The webcast will be archived and available for 14 days at https://edge.media-server.com/mmc/p/iack3rjy. A repeat of the call also can be accessed for 14 days by dialing (877) 660-6853, conference ID 13737894.

CVR Energy’s first quarter 2023 earnings news release will be distributed via GlobeNewswire and posted at www.CVREnergy.com.

About CVR Energy, Inc.

Headquartered in Sugar Land, Texas, CVR Energy is a diversified holding company primarily engaged in the renewable fuels and petroleum refining and marketing businesses, as well as in the nitrogen fertilizer manufacturing business through its interest in CVR Partners, LP. CVR Energy subsidiaries serve as the general partner and own 37 percent of the common units of CVR Partners.

For further information, please contact:

Investor Relations:
Richard Roberts
CVR Energy, Inc.
(281) 207-3205
[email protected]

Media Relations:

Brandee Stephens
CVR Energy, Inc.
(281) 207-3516
[email protected]



CVR Partners to Release First Quarter 2023 Earnings Results

SUGAR LAND, Texas, April 18, 2023 (GLOBE NEWSWIRE) — CVR Partners, LP (NYSE: UAN), a manufacturer of ammonia and urea ammonium nitrate (UAN) solution fertilizer products, plans to release its first quarter 2023 earnings results on Monday, May 1, after the close of trading on the New York Stock Exchange. The Partnership also will host a teleconference call on Tuesday, May 2, at 11 a.m. Eastern to discuss these results.

This call, which will contain forward-looking information, will be webcast live and can be accessed on the Investor Relations section of CVR Partners’ website at www.CVRPartners.com. For investors or analysts who want to participate during the call, the dial-in number is (877) 407-8029. The webcast will be archived and available for 14 days at https://edge.media-server.com/mmc/p/8nwfybak. A repeat of the call also can be accessed for 14 days by dialing (877) 660-6853, conference ID 13737893.

CVR Partners’ first quarter 2023 earnings news release will be distributed via GlobeNewswire and posted at www.CVRPartners.com.

About CVR Partners, LP

Headquartered in Sugar Land, Texas, CVR Partners, LP is a Delaware limited partnership focused on the production, marketing and distribution of nitrogen fertilizer products. It primarily produces urea ammonium nitrate (UAN) and ammonia, which are predominantly used by farmers to improve the yield and quality of their crops. CVR Partners’ Coffeyville, Kansas, nitrogen fertilizer manufacturing facility includes a 1,300 ton-per-day ammonia unit, a 3,100 ton-per-day UAN unit and a dual-train gasifier complex having a capacity of 89 million standard cubic feet per day of hydrogen. CVR Partners’ East Dubuque, Illinois, nitrogen fertilizer manufacturing facility includes a 1,075 ton-per-day ammonia unit and a 950 ton-per-day UAN unit.

For further information, please contact:

Investor Relations:
Richard Roberts
CVR Partners, LP
(281) 207-3205
[email protected]

Media Relations:
Brandee Stephens
CVR Partners, LP
(281) 207-3516
[email protected]



Bright Green Announces Fourth Quarter 2022 Financial Update

Continued investment to support long-term strategy and pathway for growth, including plans to fully acquire Alterola Biotech, appointment of Seamus McAuley as Chief Executive Officer and expansion of Scientific Advisory Board

Recently announced capital raise plan of $500+ million utilizing the U.S. Citizen & Immigration Services EB-5 program, alongside the recently announced full acquisition of Alterola Biotech, showcases the Company’s significant progress against its strategic plan

Company preparing for federal registration from U.S. Drug Enforcement Administration as bulk cannabis manufacturer, which will position Bright Green to become the largest, fully integrated operation for marijuana cultivation in the U.S. for research, medical and pharmaceutical applications and affiliated import and export

GRANTS, N.M., April 18, 2023 (GLOBE NEWSWIRE) — Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or “the Company”), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated import and export, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022.

Bright Green Chief Executive Officer (CEO) Seamus McAuley said, “During and following the fourth quarter, Bright Green achieved several critical milestones that significantly advanced our progress against our strategic plan. This includes the announcement of our intent to fully acquire Alterola Biotech – allowing us to leverage their pharmaceutical expertise as we prepare for operations – the expansion of our Scientific Advisory Board with leaders deeply experienced in developing cannabinoid and cannabinoid-like medicines, and plans to raise $500 million in capital utilizing the USCIS EB-5 Program, with initial funds already received.”

Mr. McAuley added, “We now await and anticipate final registration of our federal license to be a bulk cannabis manufacturer from the U.S. Drug Enforcement Administration (DEA). Upon receiving the license to commence cultivation, Bright Green will be prepared to deliver products to be used in innovative medical treatments for patients globally. We look forward to sharing additional updates on our progress over the coming weeks and months as we execute and seek to realize our strategic vision: having Bright Green be the largest global cannabinoid pharmaceutical and medical development company.”


Strategic Highlights During and Following Fourth Quarter 2022

  • In October 2022, Bright Green announced the expansion of its Scientific Advisory Board (“SAB”) with a group of industry leaders, chaired by Colin Stott, chief operating officer at Alterola Biotech, Inc. (“Alterola”) (OTC PINK: ABTI), a U.K.-based pharmaceutical company focused on developing cannabinoid and cannabinoid-like medicines and products, to work with the Company’s senior management to advance its long-term business growth and position it for future success.
  • After quarter end, Bright Green:
    • The company announced its plans to raise $500 million utilizing the USCIS EB-5 Program to accelerate its 2023 growth strategy and generate significant capital for use in its greenhouse construction and operations in Grants, New Mexico.
      • The EB-5 Program, which President Biden reauthorized in 2022, is an innovative vehicle for spurring investment and job creation in rural communities. Bright Green’s participation will add significant value to the region, while also generating the capital needs for its commercial and business initiatives.
      • The Company disclosed that it received funds from its first applications under the EB-5 Program, validating the proof of concept of the EB-5 Program, supporting working capital requirements to operate its current greenhouse facilities and setting the stage for the next phase of its strategic growth plan.
      • To date, Bright Green has sold 44,010 shares of common stock at $39.99 per share, receiving proceeds of $1.76 million. The Company also received executed subscription agreements from 37 investors to purchase 814,185 shares of common stock for $32.6 million.
    • Bright Green announced the appointment of Chief Operating Officer (COO) Seamus McAuley as its new Chief Executive Officer (CEO), succeeding Mr. Terry Rafih, who retained his role of Executive Chairman of the Board of Directors. Mr. McAuley has held several global senior leadership positions across the pharmaceutical, medical device and healthcare industries, including most recently as the CEO of Alterola.
    • The Company outlined its plans to move forward with its acquisition of Alterola, following the completion of its initial 25% acquisition during the quarter.
      • The strategic partnership enables Bright Green to leverage Alterola’s extensive sector experience and pharmaceutical assets to help it more efficiently scale operations and harness the therapeutic benefits of Alterola’s cannabinoid and cannabinoid-like medicines.
      • The recently announced merger of Alterola into Bright Green, delivers a pipeline of targeted pharmaceutical candidates, which is expected to progress through the relevant U.S. Food & Drug Administration pathways, and enables development of products for application in various clinical settings, delivering significant value to the Company and shareholders.
      • As Bright Green prepares to enter its next phase to become operational and produce revenues, expansion of the team to build out capabilities becomes a priority for the Company’s leadership.


Financial Highlights for 2022

  • Bright Green recorded no revenues for the quarter, as it continued to build facilities to grow, research and distribute cannabis, pending DEA final inspection, registration, and quota approvals.
  • Total operating expenses were $27.3 million during the 12-month period ended on December 31, 2022, up from $2.5 million in 2021, in line with expectations and resulting mainly from Bright Green’s corporate activities, including professional fees paid in relation to the Company’s direct listing on NASDAQ in May and private investment in public equity capital raise in September, salaries and equity compensation, and ramp-up expenses incurred towards commercialization. Of the $27.3 million in operating expenses, $18.8 million correspond to equity-based compensation to officers, contractors, and professional services providers.
  • Bright Green’s capital expenditures in 2022 was $10.5 million, primarily used for the build out of the Company’s Grants, New Mexico greenhouse.
  • The Company acquired a 25% equity position in Alterola for $4.3 million, including direct closing costs. At the end of 2022 Bright Green has a liability of $1.7 million due to the sellers.
  • Net loss of $27.7 million, in line with expectations.
  • Basic and diluted loss per share of $0.17 for the quarter.


Balance Sheet and Capital Allocation

  • As of December 31, 2022, the Company had cash of $414,574, a decline from $1,282,565 at the end of December 31, 2021.
  • Total liquidity of $11.7 million, including the remaining balance on the credit facility executed with a related party, LDS Capital, LLC (Lynn Stockwell), as amended, of approximately $11.3 million.
  • During 2022, Bright Green received cash proceeds of $12.2 million from the sales of common stock and warrants, as well as and paid down approximately $3.6 million on the LDS Capital, LLC line of credit. The cash proceeds were used primarily for the construction of our greenhouse, deposits for equipment, and costs associated with regulatory filings.

Bright Green’s balance sheet and statement of operations are provided below. Additional information is included in the Company’s quarterly report on Form 10-K for the quarter and fiscal year ended December 31, 2022, which can be accessed at: https://investors.brightgreen.us/news-events/news-releases

About Bright Green

Bright Green is one of the very few companies eligible for authorization by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. Our registration by the U.S. Drug Enforcement Administration gives us the opportunity to advance our vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit www.brightgreen.us.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management as of such date. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include those related to our EB-5 Program capital raise. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2022 and declared effective May 13, 2022, and in the Company’s subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that may be filed by the Company from time to time with the SEC. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. The Company undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. Additional information regarding these and other factors that could affect the company’s results is included in the Company’s SEC filings, which may be obtained by visiting the SEC’s website at www.sec.gov.

Media Contact

[email protected]

Investor Relations Contact

[email protected]  



BCB Bancorp, Inc. Earns $8.1 Million in First Quarter 2023; Reports $0.46 EPS and 6.1 Percent Net Loan Growth

BAYONNE, N.J., April 18, 2023 (GLOBE NEWSWIRE) — BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), today reported net income of $8.1 million for the first quarter of 2023, compared to $12.1 million in the fourth quarter of 2022, and $10.0 million for the first quarter of 2022. Earnings per diluted share for the first quarter of 2023 were $0.46, compared to $0.69 in the preceding quarter and $0.56 in the first quarter of 2022. Net income and earnings per diluted share for the first quarter of 2023, adjusted for the unrealized losses on equity investments, were $10.4 million and $0.60, respectively.

The Company announced that its Board of Directors declared a regular quarterly cash dividend of $0.16 per share. The dividend will be payable on May 19, 2023 to common shareholders of record on May 5, 2023.

“We posted another quarter of strong loan growth as we continued to onboard new relationships and customers that have become available to us from recent market disruptions. We are acutely aware of the liquidity challenges posed by the macroenvironment and remain very focused on maintaining a strong capital and liquidity position,” stated Thomas Coughlin, President and Chief Executive Officer. “In a persistently high rate environment, our customers have remained loyal to us and continue to book business with us. Our core deposits grew at an annualized rate of 7.1 percent during the quarter. Like many of our peers, the increasing cost of liquidity has pressured our net interest margin. While we believe that our net interest margin has stabilized, we remain focused on protecting our net interest income, which will benefit from higher-priced loan originations and from the upward repricing of the existing loan book.”

“On January 1, 2023, the Company implemented the Current Expected Credit Losses (“CECL”) methodology and the Day One CECL adjustment resulted in a $4.2 million reduction to our Allowance for Credit Losses (“ACL”) which further benefitted our capital (net of taxes). Our asset quality remains strong and the Bank’s loan portfolio continues to perform very well. Our non-accrual to total loans ratio decreased to 0.16 percent at March 31, 2023 from 0.17 percent at December 31, 2022 and 0.38 percent a year ago. Using the CECL methodology, we recorded a loan loss provision of $622,000 during the first quarter of 2023 compared to a credit to the loan loss provision of $500,000 during the fourth quarter of 2022 under the incurred loss methodology,” said Coughlin.

“We remain committed to building a strong franchise despite the current challenges and headwinds facing the banking industry. Our continued ability to hire talent, grow our balance sheet organically, and digitize our products and services will only further enhance the value of our Bank over time. We are well-positioned to come out stronger and more profitable on the other side of the current economic cycle,” said Coughlin.

Executive Summary

  • Total deposits were $2.867 billion at March 31, 2023, up from $2.631 billion at March 31, 2022.
  • Net interest margin was 3.15 percent for the first quarter of 2023, compared to 3.76 percent for the fourth quarter of 2022, and 3.46 percent for the first quarter of 2022.
    • Total yield on interest-earning assets increased 1 basis point to 4.86 percent for the first quarter of 2023, compared to 4.85 percent for the fourth quarter of 2022, and increased 104 basis points from 3.82 percent for the first quarter of 2022.
    • Total cost of interest-bearing liabilities increased 78 basis points to 2.24 percent for the first quarter of 2023, compared to 1.46 percent for the fourth quarter of 2022, and increased 174 basis points from 0.50 percent for the first quarter of 2022.
  • The efficiency ratio for the first quarter was 53.7 percent compared to 51.3 percent in the prior quarter, and 53.0 percent in the first quarter of 2022.
  • The annualized return on average assets ratio for the first quarter was 0.90 percent, compared to 1.46 percent in the prior quarter, and 1.33 percent in the first quarter of 2022.
  • The annualized return on average equity ratio for the first quarter was 11.0 percent, compared to 17.0 percent in the prior quarter, and 14.7 percent in the first quarter of 2022.
  • The provision for loan losses was $622,000 in the first quarter of 2023 compared to a credit for loan losses of $500,000 for the fourth quarter of 2022 and a credit for loan losses of $2.6 million for the first quarter of 2022.
  • Allowance for credit losses as a percentage of non-accrual loans was 571.0 percent at March 31, 2023, compared to 633.6 percent for the prior quarter-end and 368.1 percent at March 31, 2022, as total non-accrual loans decreased to $5.06 million at March 31, 2023, from $5.11 million for the prior quarter and $9.23 million at March 31, 2022.
  • Total loans receivable, net of allowance for credit losses, increased 34.9 percent to $3.232 billion at March 31, 2023, up from $2.396 billion at March 31, 2022.

Balance Sheet Review

Total assets increased by $216.9 million, or 6.1 percent, to $3.763 billion at March 31, 2023, from $3.546 billion at December 31, 2022. The increase in total assets was mainly related to increases in total loans and in cash and cash equivalents.

Total cash and cash equivalents increased by $31.7 million, or 13.8 percent, to $261.1 million at March 31, 2023, from $229.4 million at December 31, 2022. The increase was primarily due to an increase in Federal Home Loan Bank (“FHLB”) borrowings and in deposits.

Loans receivable, net, increased by $186.5 million, or 6.1 percent, to $3.232 billion at March 31, 2023, from $3.045 billion at December 31, 2022. Total loan increases for the first three months of 2023 included increases of $121.7 million in commercial real estate and multi-family loans, $45.6 million in commercial business loans, $17.6 million in construction loans, and $2.1 million in home equity and consumer loans, partly offset by a decrease of $3.4 million in residential one-to-four family loans. The allowance for credit losses decreased $3.5 million to $28.9 million, or 571.0 percent of non-accruing loans and 0.89 percent of gross loans, at March 31, 2023, as compared to an allowance for credit losses of $32.4 million, or 633.6 percent of non-accruing loans and 1.05 percent of gross loans, at December 31, 2022.

Total investment securities decreased by $8.0 million, or 7.3 percent, to $101.4 million at March 31, 2023, from $109.4 million at December 31, 2022, representing unrealized losses, calls and maturities, and repayments.

Deposit liabilities increased by $55.6 million, or 2.0 percent, to $2.867 billion at March 31, 2023, from $2.812 billion at December 31, 2022. The increase in deposits was primarily driven by an increase of $43.3 million in non-brokered deposits during the first quarter of 2023.

Debt obligations increased by $150.2 million to $570.0 million at March 31, 2023 from $419.8 million at December 31, 2022. The weighted average interest rate of FHLB advances was 4.52 percent at March 31, 2023 and 4.07 percent at December 31, 2022. The weighted average maturity of FHLB advances as of March 31, 2023 was 0.78 years. The fixed interest rate of our subordinated debt balances was 5.62 percent at March 31, 2023 and December 31, 2022.

Stockholders’ equity increased by $6.4 million, or 2.2 percent, to $297.6 million at March 31, 2023, from $291.3 million at December 31, 2022. The increase was primarily attributable to the increase in retained earnings of $8.0 million, or 7.0 percent, to $123.1 million at March 31, 2023 from $115.1 million at December 31, 2022.

First Quarter 2023 Income Statement Review

Net income was $8.1 million for the first quarter ended March 31, 2023 and $10.0 million for the first quarter ended March 31, 2022. The decline was primarily driven by higher loan loss provisioning and unrealized losses on equity investments for the first quarter of 2023 as compared with the first quarter of 2022.

Net interest income increased by $2.4 million, or 9.6 percent, to $27.5 million for the first quarter of 2023, from $25.1 million for the first quarter of 2022. The increase in net interest income resulted from higher interest income which was partially offset by higher interest expense.

Interest income increased by $14.6 million, or 52.8 percent, to $42.4 million for the first quarter of 2023 from $27.7 million for the first quarter of 2022. The average balance of interest-earning assets increased $583.5 million, or 20.1 percent, to $3.483 billion for the first quarter of 2023 from $2.900 billion for the first quarter of 2022, while the average yield increased 104 basis points to 4.86 percent for the first quarter of 2023 from 3.82 percent for the first quarter of 2022. Compared to the first quarter of 2023, the interest income on loans for the first quarter of 2022 also included $147,000 of amortization of purchase credit fair value adjustments related to a prior acquisition, which added approximately three basis points to the average yield on interest-earning assets.

Interest expense increased by $12.2 million to $14.9 million for the first quarter of 2023 from $2.7 million for the first quarter of 2022. The increase resulted primarily from an increase in the average rate on interest-bearing liabilities of 174 basis points to 2.24 percent for the first quarter of 2023 from 0.50 percent for the first quarter of 2022, while the average balance of interest-bearing liabilities increased by $551.7 million to $2.661 billion for the first quarter of 2023 from $2.109 billion for the first quarter of 2022. The increase in the average cost of funds resulted primarily from the persistently high interest rate environment.

The net interest margin was 3.15 percent for the first quarter of 2023 compared to 3.46 percent for the first quarter of 2022. The decrease in the net interest margin compared to the first quarter of 2022 was the result of the increase in the cost of interest-bearing liabilities partially offset by the increase in the yield on interest-earning assets. In a persistently high interest rate environment, management has been proactive in managing both the yield on earning assets and the cost of funds to protect net interest margin and continue to support the growth of net interest income.

During the first quarter of 2023, the Company experienced $48,000 in net recoveries compared to $564,000 in the first quarter of 2022. The Bank had non-accrual loans totaling $5.06 million, or 0.16 percent of gross loans, at March 31, 2023 as compared to $9.2 million, or 0.38 percent of gross loans, at March 31, 2022. The allowance for credit losses on loans was $28.9 million, or 0.89 percent of gross loans at March 31, 2023, and $34.0 million, or 1.40 percent of gross loans at March 31, 2022. The provision for loan losses was $622,000 for the first quarter of 2023 compared to a credit for loan losses of $2.6 million for the first quarter of 2022. Management believes that the allowance for credit losses on loans was adequate at March 31, 2023 and March 31, 2022.

Non-interest income decreased by $1.1 million to a loss of $1.7 million for the first quarter of 2023 from a loss of $600,000 for first quarter of 2022. The decrease in total non-interest income was mainly related to an increase in the realized and unrealized losses on equity securities from $2.7 million to $3.2 million and a decrease in BOLI income of $334,000. The realized and unrealized losses on equity securities are based on market conditions.

Non-interest expense increased by $895,000, or 6.9 percent, to $13.9 million for the first quarter of 2023 from $13.0 million for the first quarter of 2022. The increase in operating expenses for the first quarter of 2023 was primarily driven by the higher salaries and employee benefits and increased spending for advertising and promotions compared to the first quarter of 2022. The increase in salaries related to normal compensation increases, higher commission expenses from strong loan production, and staff hiring. The higher advertising and promotional spending is intended to continue the strong growth in our business. The number of full-time equivalent employees for the first quarter of 2023 was 298, as compared to 303 for the same period in 2022.

The income tax provision decreased by $911,000 or 22.0 percent, to $3.2 million for the first quarter of 2023 from $4.1 million for the first quarter of 2022. The consolidated effective tax rate was 28.5 percent for the first quarter of 2023 compared to 29.4 percent for the first quarter of 2022.

Asset Quality

During the first quarter of 2023, the Company recognized $48,000 in net recoveries, compared to $564,000 for the first quarter of 2022.

On January 1, 2023, the Company adopted Accounting Standards Update No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“CECL”), which upon adoption resulted in a Day One adjustment of $4.2 million (reduction to the 12/31/2022 Allowance for Credit Losses and benefit to capital, net of tax effect). The provision for loan losses was $622,000 for the first quarter of 2023 compared to a credit for loan losses of $2.6 million for the first quarter of 2022. The Bank had non-accrual loans totaling $5.06 million, or 0.16 percent of gross loans, at March 31, 2023, as compared to $9.2 million, or 0.38 percent of gross loans at March 31, 2022. The allowance for credit losses on loans was $28.9 million, or 0.89 percent of gross loans at March 31, 2023, and $34.0 million, or 1.40 percent of gross loans at March 31, 2022. The allowance for credit losses was 571.0 percent of non-accrual loans at March 31, 2023, and 368.1 percent of non-accrual loans at March 31, 2022.

About BCB Bancorp, Inc.

Established in 2000 and headquartered in Bayonne, N.J., BCB Community Bank is the wholly-owned subsidiary of BCB Bancorp, Inc. (NASDAQ: BCBP). The Bank has 27 branch offices in Bayonne, Edison, Hoboken, Fairfield, Holmdel, Jersey City, Lyndhurst, Maplewood, Monroe Township, Newark, Parsippany, Plainsboro, River Edge, Rutherford, South Orange, Union, and Woodbridge, New Jersey, and three branches in Hicksville and Staten Island, New York. The Bank provides businesses and individuals a wide range of loans, deposit products, and retail and commercial banking services. For more information, please go to www.bcb.bank.

Forward-Looking Statements

This release, like many written and oral communications presented by BCB Bancorp, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results.

In addition to factors previously disclosed in the Company’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”) and those identified elsewhere in this release, the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: the inability to close loans in our pipeline; changes in asset quality and credit risk; the inability to sustain revenue and earnings growth; changes in interest rates and capital markets; inflation; supply chain disruptions; any future pandemics and the related adverse local and national economic consequences; civil unrest in the communities that the company serves; customer acceptance of the Bank’s products and services; customer borrowing, repayment, investment and deposit practices; customer disintermediation; the introduction, withdrawal, success and timing of business initiatives; competitive conditions; economic conditions; and the impact, extent and timing of technological changes, capital management activities, and actions of governmental agencies and legislative and regulatory actions and reforms.

Annualized, pro forma, projected and estimated numbers are used for illustrative purpose only, are not forecasts and may not reflect actual results.

Explanation of Non-GAAP Financial Measures

Reported amounts are presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”). This press release also contains certain supplemental Non-GAAP information that the Company’s management uses in its analysis of the Company’s financial results. The Company’s management believes that providing this information to analysts and investors allows them to better understand and evaluate the Company’s financial results for the periods in question.

The Company provides measurements and ratios based on tangible stockholders’ equity and efficiency ratios. These measures are utilized by regulators and market analysts to evaluate a company’s financial condition and, therefore, the Company’s management believes that such information is useful to investors. For a reconciliation of GAAP to Non-GAAP financial measures included in this press release, see “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

  Statements of Income – Three Months Ended,    
  March 31,2023 December 31,2022 March 31, 2022 Mar. 31, 2023 vs. Dec. 31,2022 Mar. 31, 2023 vs. Mar. 31, 2022
Interest and dividend income: (In thousands, except per share amounts, Unaudited)    
Loans, including fees $ 38,889   $ 36,173   $ 26,321   7.5 % 47.7 %
Mortgage-backed securities   186     185     159   0.5 % 17.0 %
Other investment securities   1,120     1,177     948   -4.8 % 18.1 %
FHLB stock and other interest earning assets   2,157     1,321     296   63.3 % 628.7 %
Total interest and dividend income   42,352     38,856     27,724   9.0 % 52.8 %
           
Interest expense:          
Deposits:          
Demand and Money Market   3,154     2,410     758   30.9 % 316.1 %
Savings and club   118     118     108   0.0 % 9.3 %
Certificates of deposit   6,453     3,973     980   62.4 % 558.5 %
    9,725     6,501     1,846   49.6 % 426.8 %
Borrowings   5,156     2,174     806   137.2 % 539.7 %
Total interest expense   14,881     8,675     2,652   71.5 % 461.1 %
           
Net interest income   27,471     30,181     25,072   -9.0 % 9.6 %
Provision (credit) for loan losses   622     (500 )   (2,575 ) -224.4 % -124.2 %
           
Net interest income after provision (credit) for loan losses   26,849     30,681     27,647   -12.5 % -2.9 %
           
Non-interest income:          
Fees and service charges   1,098     1,138     1,214   -3.5 % -9.6 %
Gain on sales of loans   6     3     65   100.0 % -90.8 %
Realized and unrealized loss on equity investments   (3,227 )   (723 )   (2,685 ) 346.3 % 20.2 %
BOLI income   421     584     755   -27.9 % -44.2 %
Other   38     60     51   -36.7 % -25.5 %
Total non-interest income   (1,664 )   1,062     (600 ) -256.7 % 177.3 %
           
Non-interest expense:          
Salaries and employee benefits   7,618     7,626     6,736   -0.1 % 13.1 %
Occupancy and equipment   2,552     2,651     2,695   -3.7 % -5.3 %
Data processing and communications   1,665     1,579     1,465   5.4 % 13.7 %
Professional fees   566     2,169     494   -73.9 % 14.6 %
Director fees   265     261     321   1.5 % -17.4 %
Regulatory assessment fees   536     431     304   24.4 % 76.3 %
Advertising and promotions   278     260     141   6.9 % 97.2 %
Other real estate owned, net   1     4     1   -75.0 % 0.0 %
Other   373     1,056     802   -64.7 % -53.5 %
Total non-interest expense   13,854     16,037     12,959   -13.6 % 6.9 %
           
Income before income tax provision   11,331     15,706     14,088   -27.9 % -19.6 %
Income tax provision   3,225     3,634     4,136   -11.3 % -22.0 %
           
Net Income   8,106     12,072     9,952   -32.9 % -18.5 %
Preferred stock dividends   173     172     276   0.5 % -37.1 %
Net Income available to common stockholders $ 7,933   $ 11,900   $ 9,676   -33.3 % -18.0 %
           
Net Income per common share-basic and diluted          
Basic $ 0.47   $ 0.70   $ 0.57   -33.5 % -17.9 %
Diluted $ 0.46   $ 0.69   $ 0.56   -33.0 % -17.4 %
           
Weighted average number of common shares outstanding          
Basic   16,949     16,916     16,980   0.2 % -0.2 %
Diluted   17,208     17,289     17,343   -0.5 % -0.8 %

Statements of Financial Condition March 31,2023 December 31,2022 March 31, 2022 March 31, 2023 vs. December 31, 2022 March 31, 2023 vs. March 31,2022
ASSETS (In thousands, Unaudited)    
Cash and amounts due from depository institutions $ 13,213   $ 11,520   $ 8,448   14.7 % 56.4 %
Interest-earning deposits   247,862     217,839     388,205   13.8 % -36.2 %
Total cash and cash equivalents   261,075     229,359     396,653   13.8 % -34.2 %
           
Interest-earning time deposits   735     735     735      
Debt securities available for sale   86,988     91,715     86,307   -5.2 % 0.8 %
Equity investments   14,458     17,686     21,269   -18.3 % -32.0 %
Loans held for sale       658     325   -100.0 % -100.0 %
Loans receivable, net of allowance for credit losses          
of $28,882, $32,373 and $33,980, respectively   3,231,864     3,045,331     2,395,930   6.13 % 34.89 %
Federal Home Loan Bank of New York stock, at cost   26,875     20,113     6,128   33.6 % 338.6 %
Premises and equipment, net   10,106     10,508     11,646   -3.8 % -13.2 %
Accrued interest receivable   14,717     13,455     9,593   9.4 % 53.4 %
Other real estate owned   75     75     75      
Deferred income taxes   15,178     16,462     13,016   -7.8 % 16.6 %
Goodwill and other intangibles   5,359     5,382     5,417   -0.4 % -1.1 %
Operating lease right-of-use asset   15,111     13,520     11,883   11.8 % 27.2 %
Bank-owned life insurance (“BOLI”)   72,077     71,656     73,240   0.6 % -1.6 %
Other assets   8,438     9,538     8,093   -11.5 % 4.3 %
Total Assets $ 3,763,056   $ 3,546,193   $ 3,040,310   6.1 % 23.8 %
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
LIABILITIES          
Non-interest bearing deposits $ 604,935   $ 613,910   $ 621,402   -1.5 % -2.6 %
Interest bearing deposits   2,262,274     2,197,697     2,009,773   2.9 % 12.6 %
Total deposits   2,867,209     2,811,607     2,631,175   2.0 % 9.0 %
FHLB advances   532,399     382,261     71,848   39.3 % 641.0 %
Subordinated debentures   37,566     37,508     37,333   0.2 % 0.6 %
Operating lease liability   15,436     13,859     12,180   11.4 % 26.7 %
Other liabilities   12,828     9,704     11,615   32.2 % 10.4 %
Total Liabilities   3,465,438     3,254,939     2,764,151   6.5 % 25.4 %
           
STOCKHOLDERS’ EQUITY          
Preferred stock: $0.01 par value, 10,000 shares authorized                
Additional paid-in capital preferred stock   21,003     21,003     26,213     -19.9 %
Common stock: no par value, 40,000 shares authorized                
Additional paid-in capital common stock   197,197     196,164     194,222   0.5 % 1.5 %
Retained earnings   123,121     115,109     88,132   7.0 % 39.7 %
Accumulated other comprehensive loss   (6,613 )   (6,491 )   (1,275 ) 1.9 % 418.7 %
Treasury stock, at cost   (37,090 )   (34,531 )   (31,133 ) 7.4 % 19.1 %
Total Stockholders’ Equity   297,618     291,254     276,159   2.2 % 7.8 %
           
Total Liabilities and Stockholders’ Equity $ 3,763,056   $ 3,546,193   $ 3,040,310   6.1 % 23.8 %
           
Outstanding common shares   16,884     16,931     16,985      

  Average Balances and Rates -Three Months Ended March 31,
    2023       2022  
  Average Balance Interest Earned/Paid Average Yield/Rate (3)   Average Balance Interest Earned/Paid Average Yield/Rate (3)
  (Dollars in thousands)
Interest-earning assets:              
Loans Receivable (4)(5) $ 3,165,678   $ 38,889 4.91 %   $ 2,343,845   $ 26,321 4.49 %
Investment Securities   108,869     1,306 4.80 %     108,960     1,107 4.06 %
FHLB stock and other interest-earning assets   208,842     2,157 4.13 %     447,080     296 0.26 %
Total Interest-earning assets   3,483,390     42,352 4.86 %     2,899,885     27,724 3.82 %
Non-interest-earning assets   116,769           102,118      
Total assets $ 3,600,159         $ 3,002,003      
Interest-bearing liabilities:              
Interest-bearing demand accounts $ 713,788   $ 1,789 1.00 %   $ 706,067   $ 398 0.23 %
Money market accounts   314,427     1,365 1.74 %     345,564     360 0.42 %
Savings accounts   322,760     118 0.15 %     336,575     108 0.13 %
Certificates of Deposit   848,447     6,453 3.04 %     611,813     980 0.64 %
Total interest-bearing deposits   2,199,422     9,725 1.77 %     2,000,019     1,846 0.37 %
Borrowed funds   461,415     5,156 4.47 %     109,105     806 2.95 %
Total interest-bearing liabilities   2,660,837     14,881 2.24 %     2,109,124     2,652 0.50 %
Non-interest-bearing liabilities   645,883           621,575      
Total liabilities   3,306,720           2,730,699      
Stockholders’ equity   293,439           271,305      
Total liabilities and stockholders’ equity $ 3,600,159         $ 3,002,003      
Net interest income   $ 27,471       $ 25,072  
Net interest rate spread(1)     2.63 %       3.32 %
Net interest margin(2)     3.15 %       3.46 %
               
(1) Net interest rate spread represents the difference between the average yield on average interest-earning assets and the average cost of average interest-bearing liabilities.
(2) Net interest margin represents net interest income divided by average total interest-earning assets.
(3) Annualized.
(4) Excludes allowance for credit losses.
(5) Includes non-accrual loans which are immaterial to the yield.

  Financial Condition data by quarter
  Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022
           
  (In thousands, except book values)
Total assets $ 3,763,056   $ 3,546,193   $ 3,265,612   $ 3,072,771   $ 3,040,310  
Cash and cash equivalents   261,075     229,359     221,024     206,172     396,653  
Securities   101,446     109,401     111,159     105,717     107,576  
Loans receivable, net   3,231,864     3,045,331     2,787,015     2,620,630     2,395,930  
Deposits   2,867,209     2,811,607     2,712,946     2,655,030     2,631,175  
Borrowings   569,965     419,769     249,573     124,377     109,181  
Stockholders’ equity   297,618     291,254     282,682     271,637     276,159  
Book value per common share1 $ 16.38   $ 15.96   $ 15.42   $ 15.04   $ 14.72  
Tangible book value per common share2 $ 16.07   $ 15.65   $ 15.11   $ 14.73   $ 14.41  
           
  Operating data by quarter
  Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022
  (In thousands, except for per share amounts)
Net interest income $ 27,471   $ 30,181   $ 30,951   $ 27,741   $ 25,072  
Provision (credit) for loan losses   622     (500 )           (2,575 )
Non-interest income   -1,664     1,062     1,446     (313 )   (600 )
Non-interest expense   13,854     16,037     13,453     13,056     12,959  
Income tax expense   3,225     3,634     5,552     4,209     4,136  
Net income $ 8,106   $ 12,072   $ 13,392   $ 10,163   $ 9,952  
Net income per diluted share $ 0.46   $ 0.69   $ 0.76   $ 0.58   $ 0.56  
Common Dividends declared per share $ 0.16   $ 0.16   $ 0.16   $ 0.16   $ 0.16  
           
  Financial Ratios(3)
  Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022
Return on average assets   0.90 %   1.46 %   1.74 %   1.32 %   1.33 %
Return on average stockholder’s equity   11.05 %   16.99 %   19.42 %   15.00 %   14.67 %
Net interest margin   3.15 %   3.76 %   4.18 %   3.74 %   3.46 %
Stockholder’s equity to total assets   7.91 %   8.21 %   8.66 %   8.84 %   9.08 %
Efficiency Ratio4   53.68 %   51.33 %   41.53 %   47.60 %   52.95 %
           
  Asset Quality Ratios
  Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022
  (In thousands, except for ratio %)
Non-Accrual Loans $ 5,058   $ 5,109   $ 8,505   $ 9,201   $ 9,232  
Non-Accrual Loans as a % of Total Loans   0.16 %   0.17 %   0.30 %   0.35 %   0.38 %
ACL as % of Non-Accrual Loans   571.0 %   633.6 %   390.3 %   370.7 %   368.1 %
Individually Evaluated Loans   17,585     28,272     40,524     42,411     40,955  
Classified Loans   17,585     17,816     30,180     31,426     29,850  
           
(1) Calculated by dividing stockholders’ equity, less preferred equity, by shares outstanding.
(2) Calculated by dividing tangible stockholders’ common equity, a non-GAAP measure, by shares outstanding. Tangible stockholders’
common equity is stockholders’ equity less goodwill and preferred stock. See “Reconciliation of GAAP to Non-GAAP Financial Measures by quarter.”
(3) Ratios are presented on an annualized basis, where appropriate.
(4) The Efficiency Ratio, a non-GAAP measure, was calculated by dividing non-interest expense by the total of net interest income
and non-interest income. See “Reconciliation of GAAP to Non-GAAP Financial Measures by quarter.”

  Recorded Investment in Loans Receivable by quarter
  Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022
  (In thousands)
Residential one-to-four family $ 246,683   $ 250,123   $ 242,238   $ 235,883   $ 233,251  
Commercial and multi-family   2,466,932     2,345,229     2,164,320     2,030,597     1,804,815  
Construction   162,553     144,931     153,103     155,070     141,082  
Commercial business   327,598     282,007     205,661     181,868     198,216  
Home equity   58,822     56,888     56,064     51,808     52,279  
Consumer   3,383     3,240     2,545     2,656     2,726  
  $ 3,265,971   $ 3,082,418   $ 2,823,931   $ 2,657,882   $ 2,432,369  
Less:          
Deferred loan fees, net   (5,225 )   (4,714 )   (3,721 )   (3,139 )   (2,459 )
Allowance for credit loss   (28,882 )   (32,373 )   (33,195 )   (34,113 )   (33,980 )
           
Total loans, net $ 3,231,864   $ 3,045,331   $ 2,787,015   $ 2,620,630   $ 2,395,930  
           
  Non-Accruing Loans in Portfolio by quarter
  Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022
  (In thousands)
Residential one-to-four family $ 237   $ 243   $ 263   $ 267   $ 278  
Commercial and multi-family   340     346     757     757     757  
Construction   3,217     3,180     3,180     3,043     2,954  
Commercial business   1,264     1,340     4,305     5,104     5,243  
Home equity               30      
Total: $ 5,058   $ 5,109   $ 8,505   $ 9,201   $ 9,232  
           
  Distribution of Deposits by quarter
  Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022
  (In thousands)
Demand:          
Non-Interest Bearing $ 604,934   $ 613,909   $ 610,425   $ 595,167   $ 621,403  
Interest Bearing   686,577     757,615     726,012     810,535     724,020  
Money Market   361,558     305,556     370,353     360,356     354,302  
Sub-total: $ 1,653,069   $ 1,677,080   $ 1,706,790   $ 1,766,058   $ 1,699,725  
Savings and Club   319,131     329,753     338,864     347,279     341,529  
Certificates of Deposit   895,009     804,774     667,291     541,693     589,921  
Total Deposits: $ 2,867,209   $ 2,811,607   $ 2,712,945   $ 2,655,030   $ 2,631,175  

  Reconciliation of GAAP to Non-GAAP Financial Measures by quarter
           
  Tangible Book Value per Share
  Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022
  (In thousands, except per share amounts)
Total Stockholders’ Equity $ 297,618   $ 291,254   $ 282,682   $ 271,637   $ 276,159  
Less: goodwill   5,252     5,252     5,252     5,252     5,252  
Less: preferred stock   21,003     21,003     21,003     16,563     26,213  
Total tangible common stockholders’ equity   271,363     264,999     256,427     249,822     244,694  
Shares common shares outstanding   16,884     16,931     16,974     16,960     16,984  
Book value per common share $ 16.38   $ 15.96   $ 15.42   $ 15.04   $ 14.72  
Tangible book value per common share $ 16.07   $ 15.65   $ 15.11   $ 14.73   $ 14.41  
           
  Efficiency Ratios
  Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022
  (In thousands, except for ratio %)
Net interest income $ 27,471   $ 30,181   $ 30,951   $ 27,741   $ 25,072  
Non-interest income   -1,664     1,062     1,446     -313     -600  
Total income   25,807     31,243     32,397     27,428     24,472  
Non-interest expense   13,854     16,037     13,453     13,056     12,959  
Efficiency Ratio   53.68 %   51.33 %   41.53 %   47.60 %   52.95 %
           

Contact:
Thomas Coughlin,
President & CEO
Jawad Chaudhry, CFO
(201) 823-0700



Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform

JUPITER, Fla., April 18, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/640,483, titled “PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA” (the “Patent”), and is expected to provide patent protection through 2038.

The Patent will cover claims for the development and manufacture of seasonal and pandemic influenza vaccines from the Company’s C1 protein production platform. The human influenza vaccine market is currently valued at approximately $8 Billion USD and expected to grow to over $12 by 2028 with multi-valent vaccines leading the market.

“The COVID pandemic has provided important insights in the fight against infectious diseases. There is an urgent need for more efficient manufacturing platforms that can rapidly and affordably produce more complex vaccines, in greater quantities, to address a global rather than regional population. The need is for humans, and with the recent outbreak of Avian Flu, for animal health as well,” said Mark Emalfarb, Chief Executive Officer of Dyadic.

“Data presented at the World Vaccine Conference earlier this month demonstrated the capability of C1 to produce flu and other antigens. We believe C1 has the potential to become a global solution for seasonal or pandemic rapid production, at affordable costs for developed and emerging countries, and for mono or multi-valent vaccines,” continued Mr. Emalfarb.

“Along with our robust patent estate for the C1-cell line, the Patent strengthens our intellectual property portfolio around innovations for our proprietary and patented C1-cell protein production platform, further supporting the research and production of antigens, antibodies, and other therapeutic proteins for infectious and other diseases such as oncology, diabetes, arthritis, and neurological diseases from filamentous fungi. Dyadic has amassed a patent family around genetically engineered hyper productive C1-cells, supported by a variety of novel, pending and protected inventions,” concluded Mr. Emalfarb.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.

Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.

With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including our lead asset DYAI-100 COVID-19 vaccine candidate, as well as other biologic vaccines, antibodies, and other biological products.

To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit https://www.dyadic.com.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com.

Contact:

Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: [email protected]



SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy

SAB-176 has now received both Breakthrough and Fast Track designations from FDA – signifying its potential to fundamentally improve influenza treatment and prophylaxis

Influenza therapeutic now eligible for intensive guidance from FDA 
for an efficient development program

SAB-176 is the first fully-human multi-epitope binding broadly neutralizing immunoglobulin antibody therapeutic being developed for treatment of high-risk patients and for post-exposure prophylaxis of Type A and Type B influenza

SIOUX FALLS, S.D., April 18, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human, multi-epitope binding immunoglobulin (hIgG, or fully human polyclonal) antibodies, without the need for human donors, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to SAB-176, an investigational therapeutic, for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains. On April 13, SAB announced that the FDA had granted Fast Track designation to SAB-176, and that the company had also received FDA guidance and regulatory alignment on advancing SAB-176 into the next phase of development through initiation of a Phase 2b dose-range finding efficacy and safety trial in patient populations at high-risk for developing severe disease.

The FDA’s Breakthrough Therapy designation process is designed to expedite the development and review of a medicine that is intended to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over therapies currently available on a clinically significant endpoint(s). Products that qualify for Breakthrough Therapy designation receive more benefits than Fast Track products.

“Influenza continues to pose considerable health concerns both in the U.S. and on a global scale. This Breakthrough Therapy designation signifies an important step forward in our fight against this disease,” said Eddie Sullivan, PhD, co-founder, President & CEO of SAB Biotherapeutics. “Even though both designations can be requested early in development, the requirements for Breakthrough Therapy designation are higher than those for the Fast Track program. For Breakthrough Therapy designation, the improvement demonstrated must be substantial. We are proud that based on generated preclinical and clinical evidence, SAB-176 has received both Breakthrough and Fast Track designations, a combination rarely seen. These designations further assure us that SAB-176 has a clear regulatory and clinical development path to progress this important therapeutic.”

SAB-176 is being developed for several influenza indications, including treatment of high-risk patient populations, as well as pre- and post-exposure prophylaxis. The FDA’s Breakthrough Therapy designation confirms that the multi-epitope targeting modality of SAB-176 has a clear differentiation vs. monoclonal antibodies (mAb) that bind to a single epitope, and SAB’s treatment can sustain its efficacy over viral mutations and prevent or reduce the risk of emerging treatment-resistant influenza strains. Virus evolution driven by vaccines or treatments is a serious challenge and the use of therapeutics can create “escape mutants” or versions of a virus that have changed to escape pressure on virus survival driven by an antiviral treatment, whether it is a small molecule or monoclonal antibody modality.

Clinical evidence for SAB-176 generated in the SAB-176-201 clinical trial showed a significantly shorter time to resolution of positive viral culture vs. the control group. SAB’s DiversitAb™ platform data also showed that the multi-epitope binding modality of SAB’s biologic treatments reduces risk for emergence of treatment-resistant viruses. Preclinical evidence of in vivo efficacy of SAB-176 in the treatment-resistant strains further supports the scientific foundation for this Breakthrough designation.

SAB-176 is a highly potent immunotherapy that is grounded in fundamentals of the natural immune response to neutralize Type A and Type B influenza viruses by generating endogenous multi-epitope binding antibodies. The treatment is produced using SAB’s proprietary DiversitAb™ platform, which enables—for the first time—rapid, scalable production of highly potent, fully-human polyclonal IgG antibodies, without the need for human donors. The platform is capable of addressing the emergence and diversity of modern health challenges, including seasonal and pandemic influenza, COVID-19, Clostridioides difficile (CDI or C. diff), autoimmune disorders, such as type 1 diabetes, and cancers.

SAB-176 has undergone multiple clinical and pre-clinical studies, including a Phase 1 trial in healthy volunteers and a Phase 2a challenge study completed last year. The data indicate that SAB-176 offers broad antibody protection against multiple strains of this rapidly mutating virus. In the Phase 2a study, SAB-176 showed broad cross-protection across seasonal and pandemic strains of Influenza A and lineages of influenza B including strains that were not specifically targeted in the manufacturing of the therapeutic. At the same time, the FDA guidance and regulatory alignment received by the company paves the way for changing the strains that are specifically targeted by the product over time to potentially ensure that the product maintains efficacy as the virus mutates over time.

The DiversitAb™ platform is a first-of-its-kind technology capable of producing large amounts of fully-human high-titer, high-avidity multi-epitope binding antibodies across multiple targets without the need for human donors. SAB is leveraging its proprietary platform to discover and develop product candidates with the potential to be first-in-class or best-in-class against complex targets to treat or prevent diseases with significant unmet medical needs. These include infectious respiratory and gastroenterological diseases, immune and autoimmune disorders, and oncology.

More information on SAB-176’s influenza therapeutic candidate can be found on the pipeline page of SAB’s website: sab.bio/sab-176.

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage biopharmaceutical company focused on the development of powerful and proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. Our development programs include infectious diseases resulting from outbreaks and pandemics, as well as immunological, gastroenterological, and respiratory diseases that have significant mortality and health impacts on immune compromised patients. SAB has applied advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™. Our versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, fully-human polyclonal immunotherapies without the need for human donors. SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: https://www.SAb.bio/ and follow SAB on Twitter and LinkedIn.

Forward-Looking Statements

Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, the development and efficacy of our influenza program, C. diff. program, type 1 diabetes program, and other discovery programs, the results, including timing, of the development of SAB-176, SAB-185, SAB-142 and SAB-195, including SAB-176 Fast Track designation and Breakthrough Therapy designation, and the outcome of potential future government and other third-party collaborations or funded programs.

These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Investor Relations:

[email protected]

Media Relations:

[email protected]